WHO classification chronic myeloproliferative disorders?

The current World Health Organization (WHO) Classification acknowledges four main sub-groups of MPNs: (i) Chronic Myeloid Leukemia; (ii) classical Philadelphia-negative MPNs (Polycythemia Vera; Essential Thrombocythemia; Primary Myelofibrosis); (iii) non-classical Philadelphia-negative MPNs (Chronic Neutrophilic …

What are the symptoms of CMML?

Signs and symptoms of CMML

• tiredness and sometimes breathlessness because of a low red blood cell count (anaemia)
• infections that don’t get better.
• bleeding (such as nosebleeds) or bruising easily because of a low platelet count.
• tummy (abdominal discomfort) from a swollen spleen.
• skin rashes or lumps.

What is the prognosis for CMML?

In one study of CMML patients diagnosed between 1975 and 2005, the median survival times with CMML-1 and CMML-2 were 20 months and 15 months, respectively. However, some patients lived much longer. About 20% of CMML-1 patients and about 10% of CMML-2 patients survived longer than 5 years.

What are the criteria for diagnosis polycythemia?

Diagnosis is made using criteria developed by the Polycythemia Vera Study Group; major criteria include elevated red blood cell mass, normal oxygen saturation, and palpable splenomegaly. Untreated patients may survive for six to 18 months, whereas adequate treatment may extend life expectancy to more than 10 years.

What’s the difference between CML and CMML?

CMML is different to chronic myeloid leukaemia (CML). CML affects the myeloid cells in the blood and bone marrow, while CMML affects a specific myeloid cell called a monocyte, which helps to fight infections.

Can CMML affect the brain?

Extramedullary involvement by CMML is uncommon. Other cases of brain involvement in the context of CMML have been reported but are substantially different from ours. Meningeal infiltration was described by Rogulj et al.

What is Gaisbock syndrome?

Gaisbock syndrome is the term ascribed to several conditions initially observed by Felix Gaisbock, MD (from Innsbruck, Tyrol, Austria) in 1905 when he described a group of hypertensive male patients who had high hematocrit levels, normal leukocyte counts, and no splenomegaly.

Who cut off for polycythemia?

Major WHO criteria are as follows: Hemoglobin >16.5 g/dL in men and >16 g/dL in women, or hematocrit >49% in men and >48% in women, or red cell mass >25% above mean normal predicted value.